Vaccine Development Challenges Include Extensive Quality Control, Sanofi's Loew Notes
Sanofi spends 70% of vaccine production on quality control, Sanofi Pasteur exec VP David Loew tells the Pink Sheet; company is working on next generation flu vaccines that may provide greater efficacy.
You may also be interested in...
Long-anticipated findings for Japanese firm’s dengue vaccine show efficacy rates above its only rival, including in those not previously exposed to the virus, but results for different strains were mixed and experts are awaiting additional data due in the next few weeks.
CDC advisory committee cannot recommend administration of Sanofi's dengue vaccine until there is an acceptable test to detect previous dengue infection and other questions are answered.
Influenza is a wily foe. It shows up each winter having taken a slightly different guise to outwit our existing immune defenses, but always keeps up its sleeve an ability to shapeshift to an entirely new form that could crash straight through them.